Oct. 13 Quick Takes: J&J pauses dosing in COVID-19 vaccine trials; plus Voyager, Avenue and Surface Oncology

J&J pauses COVID-19 vaccine trial dosing 
Johnson & Johnson (NYSE:JNJ) said it has temporarily paused dosing on its COVID-19 vaccine trials, including the Phase III ENSEMBLE trial, due to “an unexplained illness in a study participant,” which is being reviewed by an independent DSMB and J&J’s internal physician team. 

Voyager’s shares slide after clinical hold
Shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) were off 11% in after-hours trading Monday after the company revealed that FDA placed a clinical hold on VY-HTT01 related to CMC issues. The company submitted an IND to FDA last month for the gene therapy to treat Huntington's disease...